Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma.
We have treated 25 consecutive patients with advanced ovarian carcinoma with cisplatin (100 mg/m2 iv on Day 1) and etoposide (100 mg/m2 orally on Days 1-3) every 3 weeks. All patients had failed previous treatment with doxorubicin and cyclophosphamide and had bulky abdominal disease. Complete response was achieved in one of 25 patients (4%), partial response was achieved in nine of 25 patients (36%), and stable disease was obtained in six additional patients (24%). Median time to disease progression was 6.8 months. Toxicity was acceptable. Cisplatin and etoposide is an effective second-line treatment of ovarian carcinoma.